BIONET-EUROPE
31.7.2024 06:01:28 CEST | Business Wire | Press release
BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine (RPV).
BioNet’s stand-alone vaccine targets whooping cough, a highly contagious respiratory disease on the steep rise across Europe. This non-combined vaccine is tailored to the persons who require pertussis-only booster vaccination and are up-to-date with their diphtheria and tetanus immunizations.
Dr Giuseppe Del Giudice, Director Translational Research at BioNet, stated, “BioNet’s recombinant vaccine is designed to provide more effective and longer-lasting immune protection against pertussis than traditional acellular pertussis vaccines. It contains a Pertussis Toxin (PT), the main component responsible for severe pertussis disease, which is inactivated by recombinant technologies rather than chemicals.”
These recombinant technologies allow for the preservation of the native structure of the PT, fundamental for the induction of higher immune protection. Currently, no other monovalent or recombinant pertussis vaccines are available in Europe, making BioNet’s RPV a best-in-class vaccine driving significant advancement in public health with the potential to improve acceptance for pertussis immunization.
Phillippe Guillot-Chene, CEO of BioNet Europe, added, “We believe that BioNet’s RPV represents a transformative vaccine for preventing pertussis disease. After receiving the positive feedback from EMA Scientific Advice, we are honored to have our MAA submission validated by the EMA as well.”
The safety, immunogenicity and antibody persistence induced after one single booster dose of BioNet’s RPV were demonstrated in numerous randomized clinical trials, notably amongst adults in Australia, adolescents in Switzerland, as well as vulnerable populations such as pregnant women and elderly in Thailand.
The vaccine is licensed in Asia (under the Pertagen® trademark) and is included in the pertussis maternal immunization program for pregnant women in Thailand. The MAA of Pertagen® has also been submitted to the Australian Therapeutic Goods Administration.
About BioNet
BioNet is a vaccine manufacturer specializing in the development of recombinant and mRNA vaccines against respiratory diseases and other global public health threats. BioNet has a strong track record with development and biomanufacturing, having advanced over three proprietary recombinant pertussis vaccines from early R&D to licensure. It currently markets multiple vaccines through its established commercial network. BioNet has been rapidly expanding its operations across Asia, Europe and North America.
Forward-Looking Statements
This press release contains forward-looking statements relating to BioNet’s business, including regulatory submissions. These statements are based on current expectations as of the date of this press release and involve known and unknown risks and uncertainties that may cause actual results to differ materially. BioNet disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether due to new information, future events, or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730521754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom